Literature DB >> 23926199

Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.

Song Ling Poon1, See-Tong Pang, John R McPherson, Willie Yu, Kie Kyon Huang, Peiyong Guan, Wen-Hui Weng, Ee Yan Siew, Yujing Liu, Hong Lee Heng, Soo Ching Chong, Anna Gan, Su Ting Tay, Weng Khong Lim, Ioana Cutcutache, Dachuan Huang, Lian Dee Ler, Maarja-Liisa Nairismägi, Ming Hui Lee, Ying-Hsu Chang, Kai-Jie Yu, Waraporn Chan-On, Bin-Kui Li, Yun-Fei Yuan, Chao-Nan Qian, Kwai-Fong Ng, Ching-Fang Wu, Cheng-Lung Hsu, Ralph M Bunte, Michael R Stratton, P Andrew Futreal, Wing-Kin Sung, Cheng-Keng Chuang, Choon Kiat Ong, Steven G Rozen, Patrick Tan, Bin Tean Teh.   

Abstract

Aristolochic acid (AA), a natural product of Aristolochia plants found in herbal remedies and health supplements, is a group 1 carcinogen that can cause nephrotoxicity and upper urinary tract urothelial cell carcinoma (UTUC). Whole-genome and exome analysis of nine AA-associated UTUCs revealed a strikingly high somatic mutation rate (150 mutations/Mb), exceeding smoking-associated lung cancer (8 mutations/Mb) and ultraviolet radiation-associated melanoma (111 mutations/Mb). The AA-UTUC mutational signature was characterized by A:T to T:A transversions at the sequence motif A[C|T]AGG, located primarily on nontranscribed strands. AA-induced mutations were also significantly enriched at splice sites, suggesting a role for splice-site mutations in UTUC pathogenesis. RNA sequencing of AA-UTUC confirmed a general up-regulation of nonsense-mediated decay machinery components and aberrant splicing events associated with splice-site mutations. We observed a high frequency of somatic mutations in chromatin modifiers, particularly KDM6A, in AA-UTUC, demonstrated the sufficiency of AA to induce renal dysplasia in mice, and reproduced the AA mutational signature in experimentally treated human renal tubular cells. Finally, exploring other malignancies that were not known to be associated with AA, we screened 93 hepatocellular carcinoma genomes/exomes and identified AA-like mutational signatures in 11. Our study highlights an unusual genome-wide AA mutational signature and the potential use of mutation signatures as "molecular fingerprints" for interrogating high-throughput cancer genome data to infer previous carcinogen exposures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23926199     DOI: 10.1126/scitranslmed.3006086

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  117 in total

1.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.

Authors:  Yasushi Totoki; Kenji Tatsuno; Kyle R Covington; Hiroki Ueda; Chad J Creighton; Mamoru Kato; Shingo Tsuji; Lawrence A Donehower; Betty L Slagle; Hiromi Nakamura; Shogo Yamamoto; Eve Shinbrot; Natsuko Hama; Megan Lehmkuhl; Fumie Hosoda; Yasuhito Arai; Kim Walker; Mahmoud Dahdouli; Kengo Gotoh; Genta Nagae; Marie-Claude Gingras; Donna M Muzny; Hidenori Ojima; Kazuaki Shimada; Yutaka Midorikawa; John A Goss; Ronald Cotton; Akimasa Hayashi; Junji Shibahara; Shumpei Ishikawa; Jacfranz Guiteau; Mariko Tanaka; Tomoko Urushidate; Shoko Ohashi; Naoko Okada; Harsha Doddapaneni; Min Wang; Yiming Zhu; Huyen Dinh; Takuji Okusaka; Norihiro Kokudo; Tomoo Kosuge; Tadatoshi Takayama; Masashi Fukayama; Richard A Gibbs; David A Wheeler; Hiroyuki Aburatani; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2014-11-02       Impact factor: 38.330

2.  The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers.

Authors:  Brandon Leonard; Jennifer L McCann; Gabriel J Starrett; Leah Kosyakovsky; Elizabeth M Luengas; Amy M Molan; Michael B Burns; Rebecca M McDougle; Peter J Parker; William L Brown; Reuben S Harris
Journal:  Cancer Res       Date:  2015-09-29       Impact factor: 12.701

3.  Bladder cancer: aristolochic acid--one of the most potent carcinogens known to man.

Authors:  Melanie Clyne
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

Review 4.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 5.  DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.

Authors:  Byeong Hwa Yun; Jingshu Guo; Medjda Bellamri; Robert J Turesky
Journal:  Mass Spectrom Rev       Date:  2018-06-11       Impact factor: 10.946

6.  The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.

Authors:  Shih-Yung Su
Journal:  Hepatol Int       Date:  2019-01-31       Impact factor: 6.047

Review 7.  Hypermutation in human cancer genomes: footprints and mechanisms.

Authors:  Steven A Roberts; Dmitry A Gordenin
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

8.  A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets.

Authors:  D E Marin; G C Pistol; M Gras; M Palade; I Taranu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-22       Impact factor: 3.000

9.  Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid.

Authors:  Xavier Castells; Sandra Karanović; Maude Ardin; Karla Tomić; Evanguelos Xylinas; Geoffroy Durand; Stephanie Villar; Nathalie Forey; Florence Le Calvez-Kelm; Catherine Voegele; Krešimir Karlović; Maja Mišić; Damir Dittrich; Igor Dolgalev; James McKay; Shahrokh F Shariat; Viktoria S Sidorenko; Andrea Fernandes; Adriana Heguy; Kathleen G Dickman; Magali Olivier; Arthur P Grollman; Bojan Jelaković; Jiri Zavadil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-17       Impact factor: 4.254

Review 10.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.